Acrolein

CAS RN: 107-02-8

Health Effects

0.2.1 SUMMARY OF EXPOSURE
  • 0.2.1.1 ACUTE EXPOSURE
    • A) Acrolein may be irritating to the eyes, skin, and mucous membranes. It is a severe pulmonary irritant and lacrimating agent.
    • B) Skin and corneal burns may occur from direct contact with the liquid. Difficulty breathing, chest congestion, bronchospasm, as well as delayed onset of acute lung injury, and permanent lung damage may occur following acute exposure.
      • 1) Nausea and vomiting are common. CNS depression can occur from exposure to high concentrations. Ingestion may produce severe irritation of the mouth andagastrointestinal tract. Death may result from acute lung injury and/or respiratory failure.
    • C) The strong irritant properties usually prevent more serious exposures, but fatalities have occurred.
0.2.3 VITAL SIGNS
  • 0.2.3.1 ACUTE EXPOSURE
    • A) Short-term exposure may cause increases in heart rate and blood pressure.
0.2.4 HEENT
  • 0.2.4.1 ACUTE EXPOSURE
    • A) Splash contact with the eyes may cause corneal injury. Exposure to the vapor at concentrations of 0.25 ppm or greater may cause eye irritation.
0.2.5 CARDIOVASCULAR
  • 0.2.5.1 ACUTE EXPOSURE
    • A) Hypertension and tachycardia may occur following inhalation exposure.
0.2.6 RESPIRATORY
  • 0.2.6.1 ACUTE EXPOSURE
    • A) Dyspnea, bronchospasm, acute lung injury, and permanent pulmonary damage may occur following acute exposure.
0.2.7 NEUROLOGIC
  • 0.2.7.1 ACUTE EXPOSURE
    • A) Serious poisoning may cause CNS depression.
0.2.8 GASTROINTESTINAL
  • 0.2.8.1 ACUTE EXPOSURE
    • A) Nausea, vomiting, and diarrhea have been reported. Irritation of the mouth and GI tract may occur following ingestion.
0.2.14 DERMATOLOGIC
  • 0.2.14.1 ACUTE EXPOSURE
    • A) Splash contact may cause irritation, erythema, and edema. Skin burns may occur.
0.2.17 METABOLISM
  • 0.2.17.1 ACUTE EXPOSURE
    • A) Microsomal oxidases were decreased in the lung and liver in exposed rats.
0.2.20 REPRODUCTIVE HAZARDS
  • A) Birth defects were produced by direct intra-amniotic injection in rats, but the offspring of rabbits treated by gavage did not have developmental toxicity.
0.2.21 CARCINOGENICITY
  • 0.2.21.1 IARC CATEGORY
    • A) IARC Carcinogenicity Ratings for CAS107-02-8 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
      • 1) IARC Classification
        • a) Listed as: Acrolein
        • b) Carcinogen Rating: 3
      • 1) The agent (mixture or exposure circumstance) is not classifiable as to its carcinogenicity to humans. This category is used most commonly for agents, mixtures and exposure circumstances for which the evidence of carcinogenicity is inadequate in humans and inadequate or limited in experimental animals. Exceptionally, agents (mixtures) for which the evidence of carcinogenicity is inadequate in humans but sufficient in experimental animals may be placed in this category when there is strong evidence that the mechanism of carcinogenicity in experimental animals does not operate in humans. Agents, mixtures and exposure circumstances that do not fall into any other group are also placed in this category.
  • 0.2.21.2 HUMAN OVERVIEW
    • A) There is inadequate evidence of carcinogenicity in man.
  • 0.2.21.3 ANIMAL OVERVIEW
    • A) There is inadequate evidence of carcinogenicity in animals.
0.2.22 GENOTOXICITY
  • A) Mutagenic in short-term tests.
Find more information on this substance at: PubChem, PubMed